2023 ASCO-GU肾癌精粹解读  

Comprehensive interpretation of RCC abstracts,ASCO-GU 23

作　　者：刘振华[1] 盛锡楠[2] 曾浩[1] Liu Zhenhua;Sheng Xinan;Zeng Hao(Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Genitourinary Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]四川大学华西医院泌尿外科,成都610041 [2]北京大学肿瘤医院泌尿肿瘤科,北京100142

出　　处：《中华泌尿外科杂志》2023年第4期245-247,共3页Chinese Journal of Urology

摘　　要：ASCO-GU23会议在疫情后如期线下召开, 大会收录肾细胞癌领域相关摘要共167项, 内容涵盖肾细胞癌诊疗领域中首项靶向肿瘤的PET/CT诊断技术, 对前期临床试验结果的危险度分层解读, 并探索肿瘤与血清生物标志物对于精准分型治疗的价值, 同时也为序贯治疗的选择提供了证据。The ASCO-GU 23 conference was held offline as scheduled ater the pandemie.A total of 167 albstracts in the field of renal cell carcinoma has been posted during the conference,covering the first PET/CT diagnostic techmology tangeting tumors in renal cell careinoma,risk stratified interpretation of the previous elinical trial results.and exploring the walue of tumor and senum biomarkers for precise elassification therapy.as well as providing evidence for the therapeutie scheme sequencing.

关 键 词：癌 肾细胞 美国临床泌尿生殖系肿瘤年会 靶向治疗 免疫治疗 生物标志物 

分 类 号：R737.11[医药卫生—肿瘤]